Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing since 12/18/2024, newest first.
| Issuer | % of Class | Filed |
|---|---|---|
|
Hemab Therapeutics Holdings, Inc.
13G
COAG · 423494103
|
9.0% |
8/14/2026
Event 6/30/2026
|
|
Avalyn Pharma Inc.
13G
AVLN · 05348Y105
|
8.8% |
8/14/2026
Event 6/30/2026
|
|
Obsidian Therapeutics, Inc.
13G
OBX · 67448A106
|
5.1% |
8/10/2026
Event 8/3/2026
|
|
Maplight Therapeutics, Inc.
13D/A
Amendment 1
MPLT · 56565P103
|
4.9% |
7/31/2026
Event 7/30/2026
|
|
LanzaTech Global, Inc.
13G/A
Amendment 1
LNZA · 51655R200
|
1.6% |
5/15/2026
Event 3/31/2026
|
|
Edgewise Therapeutics, Inc.
13D/A
Amendment 6
EWTX · 28036F105
|
4.9% |
4/27/2026
Event 4/23/2026
|
|
4D Molecular Therapeutics, Inc.
13G/A
Amendment 1
FDMT · 35104E100
|
6.4% |
2/17/2026
Event 12/31/2025
|
|
Evotec SE
13G/A
Amendment 4
EVO · 30050E105
|
0% |
2/17/2026
Event 12/31/2025
|
|
IO Biotech, Inc.
13D/A
Amendment 8
IOBTQ · 449778109
|
3.3% |
1/23/2026
Event 1/21/2026
|
|
Evotec SE
13G/A
Amendment 3
EVO · 30050E105
|
5.3% |
11/14/2025
Event 9/30/2025
|
|
Zenas BioPharma, Inc.
13G/A
Amendment 1
ZBIO · 98937L105
|
4.7% |
11/14/2025
Event 9/30/2025
|
|
Maplight Therapeutics, Inc.
13D
MPLT · 56565P103
|
8.4% |
11/4/2025
Event 10/28/2025
|
|
4D Molecular Therapeutics, Inc.
13G
FDMT · 35104E100
|
6.8% |
10/20/2025
Event 10/13/2025
|
|
Galecto, Inc.
13D/A
Amendment 5
GLTO · 36322Q107
|
0% |
10/9/2025
Event 10/7/2025
|
|
Galecto, Inc.
13D/A
Amendment 4
GLTO · 36322Q107
|
6.5% |
9/25/2025
Event 9/23/2025
|
|
IO Biotech, Inc.
13D/A
Amendment 7
IOBTQ · 449778109
|
7.3% |
8/19/2025
Event 8/11/2025
|
|
ArriVent BioPharma, Inc.
13G/A
Amendment 2
0472N1020
|
4.9% |
8/14/2025
Event 6/30/2025
|
|
Zenas BioPharma, Inc.
13G
ZBIO · 98937L105
|
5.3% |
4/1/2025
Event 3/25/2025
|
|
ArriVent BioPharma, Inc.
13G
0472N1020
|
5.2% |
2/14/2025
Event 2/7/2025
|
|
Galecto, Inc.
13D/A
Amendment 3
GLTO · 36322Q107
|
7.6% |
1/16/2025
Event 8/29/2024
|